Top news of the day from across the health care landscape.
A new treatment that targets a specific symptom may have a positive impact on adverse events (AEs) for patients with schizophrenia, according to MD Magazine. Roluperidone is a compound in development that has demonstrated efficacy in the treatment of AEs in schizophrenia. After positive results from a phase 2 study and an additional 6-month open label extension, investigators believe that the new treatment could safely treat patients with schizophrenia without the accompanying AEs.
Applying imiquimod, a topical skin cream, following a bite from an virus-infected mosquito can inhibit the spread of the virus in a patient, according to Contagion Live. Imiquimod is indicated for use against skin cancer, external genital warts, and actinic keratosis. The cream works by activating skin macrophages and creating a heightened antiviral state, making it effective against a number of viruses.
In addition to research linking interleukin (IL)-24 as a catalyst of pro-inflammatory autoimmune disorders, such as psoriasis, arthritis, and inflammatory bowel disease, researchers were able to distinguish the gene’s role in the pathogenesis of allergic skin inflammation, according to The American Journal of Managed Care. Researchers developed a review of the IL-24 gene, which has been linked to previous studies as an essential figure in the pathogenesis of pro-inflammatory autoimmune disorders. In their analysis, researchers discovered that IL-24 has crucial roles in barrier dysfunction and S. aureus infection.